Furthermore, they stated that there is promising evidence that inactivation of REV-7 could result in increased radiosensitivity of SCCs, once again rendering REV-7 as a potential molecular target for cancer management and treatment [13]. Table 2 summarizes the potential therapeutic utility of REV-7 presented in selected studies. This evidence concerns the gene MAD2L2 and cancer.